Benign core biopsy of probably benign breast lesions 2 cm or larger: correlation with excisional biopsy and long-term follow-up

Hyun Kyung Jung*, Hee Jung Moon, Min Jung Kim, Eun-Kyung Kim
Department of Diagnostic Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea

Purpose: To evaluate the accuracy of benign core biopsy of probably benign breast lesions (category 3) 2 cm or larger on the basis of excisional biopsy and long-term follow-up.

Methods: We retrospectively reviewed 146 category 3 lesions in 146 patients 2 cm or larger which were diagnosed as benign by ultrasound (US)-guided core biopsy. Patients were initially diagnosed as benign at core needle biopsy and then followed up with excisional biopsy (surgical excision, n=91; US-guided vacuum assisted excision, n=35) or breast ultrasonography (n=20).

Results: Of the 126 patients who underwent surgical excision or US-guided vacuum-assisted excision, 114 patients were diagnosed with benign lesions, 10 patients with borderline lesions (benign phyllodes tumor), and two patients with malignant phyllodes tumors. The probabilities of lesions being benign, borderline and malignant were 91.8% (134/146), 6.8% (10/146), and 1.4% (2/146), respectively. Of 13 patients who had growing masses on follow-up ultrasonography, three (23.1%) were non-benign (two benign phyllodes tumors and one malignant phyllodes tumor).

Conclusion: US-guided core needle biopsy of probably benign breast mass 2 cm or larger was accurate (98.6%) enough to rule out malignancy. But, it was difficult to rule out borderline lesions even when they were diagnosed as benign.

Keywords: Breast diagnosis; Ultrasonography, mammary; Biopsy, large-core needle

Introduction

High resolution breast ultrasonography has been increasingly used because of its advantages in the detection, characterization and differentiation of lesions, with lesions being diagnosed as benign to malignant [1–3]. According to the Breast Imaging-Reporting and Data System (BI-RADS), category 3, probably benign, on ultrasonography is defined as a solid mass with oval shape, circumscribed margin, parallel orientation, and no suspicious malignant features [4]. Short-interval follow-up is most often recommended for category 3 lesions because the probability of malignancy is low (<2%) and unnecessary breast biopsies of benign lesions, morbidity and medical costs can all be reduced with just follow-up.
Benign core biopsy of probably benign breast mass

Even though palpable or non-palpable probably benign lesions have a short-interval imaging follow-up recommended rather than biopsy, the triple test (physical examination, mammogram, and fine-needle aspiration) or modified triple test (physical examination, mammography and/or ultrasonography, and fine-needle aspiration and/or biopsy) has been used to evaluate palpable lesions in clinical practice [5]. However, there is relatively little research on the accuracy of core needle biopsy for palpable lesions [6–9] and, in particular, on its ability to identify borderline lesions.

The purpose of our study was to investigate the accuracy of benign core needle biopsy of probably benign breast masses 2 cm or larger on the basis of excisional biopsy and long-term follow-up.

Materials and Methods

Institutional Review Board approval was obtained for this retrospective study.

Study Population

We retrospectively reviewed lesions assessed as category 3 probably benign according to BI-RADS from October 2001 to December 2009. Among 207 patients who were initially assessed with category 3 solid masses 2 cm or larger on ultrasonography with US-guided core needle biopsy (US-CNB), 199 patients were diagnosed with benign lesions and the remaining 8 patients were diagnosed with malignant (n=1, invasive ductal carcinoma) or borderline lesions (n=7; 6 phyllodes tumors, 1 intraductal papilloma). Among 199 patients with benign biopsies, 53 patients were excluded because they were lost to follow-up less that was than 2 years. Finally, 146 masses in 146 patients were included in this study (Fig. 1).

Pathologic results of US-CNB were as follows: fibroadenoma (n=64), fibrocystic change (n=25), stromal fibrosis (n=18), fibroadenomatous hyperplasia (n=19), adenosis (n=4), benign breast tissue such as fibroadipose tissue (n=5), duct ectasia (n=4), apocrine metaplasia (n=1), ductal epithelial hyperplasia (n=1), granular cell tumor (n=1), lactating adenoma (n=1), lactating adenosis (n=1), palisading granuloma (n=1), and sclerosing adenosis (n=1).

Ultrasonography and US-guided Core Needle Biopsy

Ultrasonography was performed using a 5–10 MHz or 5–12 MHz linear array transducer (HDI 3000 or 5000, Advanced Technology Laboratories, Philips Medical Systems, Bothell, WA, USA; Logic 9, GE Healthcare, Milwaukee, WI, USA; iU22, Philips Healthcare, Bothell) by one of nine dedicated breast imaging radiologists with 1 to 11 years of experience. All ultrasonography examinations included bilateral whole-breast imaging and were classified into one of five final assessments according to the BI-RADS lexicon. Category 3 probably benign was defined as a solid mass with oval shape, circumscribed margin, parallel orientation, and no suspicious malignant features. After ultrasonography, US-CNB was performed using a 14-gauge automated core needle and a spring-loaded biopsy gun (Promac 2.2L, Manan Medical Products, Northbrook, IL, USA). Local anesthesia was routinely applied and at least 5 core...
samples were obtained.

Follow-up Ultrasonography
After each biopsy, follow-up ultrasonography was recommended at 6 months, 12 months, and 24 months. At follow-up ultrasonography, a lesion-to-lesion comparison was performed. If a lesion showed no change in size and characteristics over 24 months, the final assessment was changed to category 2 benign. However, if a lesion increased in size in more than 10% of its initial maximal diameter or showed any changes in its characteristics on follow-up ultrasonography, the lesion was upgraded to category 4 or 5 and US-CNB was recommended [10–12].

Surgical Excision or US-guided Vacuum-assisted Excision
Depending on patients’ or physicians’ preference, surgical excision or US-guided vacuum-assisted excision (US-VAE) was performed. US-VAE using an 8-gauge needle (Mammotome, Ethicon Endo-Surgery, Cincinnati, OH, USA) was performed as described by Kim et al. [13]. To ensure complete mass removal during VAE, we removed breast tissue surrounding the lesion at approximately four more sampling sites (12, 3, 6, and 9 o’clock directions).

Reference Standards
Among a total of 146 masses, 91 masses underwent surgical excision, 35 masses US-VAE, and 20 masses follow-up ultrasonography. Surgical excision or US-VAE was considered to be the gold standard for most lesions. For lesions without changes over two years of follow-up ultrasonography, follow-up ultrasonography alone was considered to be the gold standard. On the basis of pathologic results and follow-up ultrasonography, we calculated the probabilities of lesions being benign, borderline and malignant. Borderline pathologies included benign or borderline phyllodes tumor.

Statistical Analysis
Statistical analyses were performed using IBM SPSS ver. 19.0 (IBM Co., Armark, NY, USA). P<0.05 was considered to indicate statistical significance. One-way ANOVA was used to compare age and size on follow-up modalities. The independent t-test was used to compare age and size on final pathology. The chi-square test was used to compare presence of symptoms and diameter changes on final pathology.

Results
All 146 patients in this study were women and 124 patients complained of palpable masses. The mean age of the patients was 35.7 years, ranging from 13 to 72 years. The mean size of the masses was 31.8 cm with a range of 2.0–12 cm.

Correlation with Gold Standards
Among the total 146 masses, surgical excision was done in 91

| Variable          | Surgical excision (n=91) | US-VAE (n=35) | Follow-up US (n=20) | P-value |
|-------------------|--------------------------|---------------|---------------------|---------|
| Age (yr)          | 34.9±12.5                | 33.1±9.9      | 44.2±13             | 0.03    |
| Size (mm)         | 35.5±14.9                | 24.3±4.5      | 28.4±9.6            | <0.001  |
| Benign            | 80 (87.9)                | 30 (85.7)     | 20 (100)            |        |
| Borderline        | 9 (9.9)                  | 5 (14.3)      | 0                   |        |
| Malignant         | 2 (2.2)                  | 0             | 0                   |        |

Values are presented as mean±SD or number (%).

US-VAE, ultrasound-guided vacuum-assisted excision; US, ultrasound.

Fig. 2. A 36-year-old woman with a palpable mass in her left breast.
Transverse (A) and longitudinal (B) ultrasonography reveal a circumscribed, oval, hypoechoic mass in the left lower inner breast. The initial diameter of the mass was 20×13×19 mm and the pathologic result of ultrasound-guided core needle biopsy was fibroadenoma. The patient underwent surgical excision 82 days later and the result was fibroadenoma.
Benign core biopsy of probably benign breast mass

In 2003, ACR developed a BI-RADS ultrasonography lexicon and a category 3 probably benign lesion is defined as a solid mass with oval shape, circumscribed margin, parallel orientation, and no suspicious malignant features [4]. It is not a definite benign designation but is expected to be changed infrequently [15]. Several early studies supported the rationale that probably benign lesions could be just followed up because of their low risk of malignancy (<2%) [10–12,16]. Other recent studies also reported similar results which concluded that category 3 probably benign lesions should be recommended for follow-up rather than immediate surgical excision

Comparison of Benign and Non-Benign Lesions

Table 2 compares the characteristics of the benign and non-benign groups. Age, size, and presence of symptoms were not statistically different between the benign and non-benign lesions. Among 126 lesions in which surgical excision and US-VAE were performed, 13 cases (10.3%) showed the maximal diameter increased by more than 10% of its initial maximal diameter (Fig. 4). The pathologic results of 13 growing masses were malignant phyllodes tumor (n=1), benign phyllodes tumor (n=2), fibroadenoma (n=5), fibrocystic change (n=2), fibroadenomatous hyperplasia (n=2), and sclerosing adenosis (n=1).

Table 2. Clinical characteristics according to the final pathology

| Variable                | Final pathology | P-value |
|-------------------------|-----------------|---------|
|                         | Benign (n=134)  | Non-benign (n=12) |
| Age (yr)                | 36.2±12.4       | 30.5±11.2 | 0.126 |
| Size (mm)               | 31.6±13.4       | 34.7±14.2 | 0.447 |
| Symptomatic patients    | 114 (85.1)      | 11 (91.7) | 0.533 |
| Increased maximal diameter (D) >10% | 10/126 (9.5)% | 3 (25) | – |

Values are presented as mean±SD or number (%).

**Discussion**

Ultrasoundography has been increasingly used and is an important adjunct to mammography in the diagnosis of breast diseases [14]. In 2003, ACR developed a BI-RADS ultrasonography lexicon and a category 3 probably benign lesion is defined as a solid mass with oval shape, circumscribed margin, parallel orientation, and no suspicious malignant features [4]. It is not a definite benign designation but is expected to be changed infrequently [15].

Finally, 134 patients were diagnosed with benign lesions (Fig. 2), two patients were diagnosed with malignancies which were all malignant phyllodes tumors (Fig. 3), and 10 patients were diagnosed with borderline lesions. So, the probabilities of lesions being benign, borderline, and malignant were 91.8% (134/146), 6.8% (10/146), and 1.4% (2/146), respectively.

**Fig. 3. A 28-year-old woman with a mass in her left breast.**

Transverse (A) and longitudinal (B) ultrasonography reveal a circumscribed, oval, hypoechoic mass in the left upper outer breast. The initial diameter of the mass was 53×26×50 mm and the pathologic result of ultrasound-guided core needle biopsy was fibroadenomatous hyperplasia. The patient underwent surgical excision 21 days later and the result was malignant phyllodes tumor.
biopsy [17–19]. However, further diagnostic imaging work-up should be preceded before assessing a lesion as probably benign and recommending follow-up [11,20,21]. The first follow-up at 6 months is the most important evaluation because rapidly growing cancer can be detected without delay [15]. However, less than 2% of probably benign lesions are diagnosed as malignancy at this point. Leung and Sickles [22] in their cohort study of 1,440 multiple-mass cases reported that the interval cancer rate (0.14%) was lower than the age-matched United States incident cancer rate (0.24%).

According to the BI-RADS lexicon, a newly detected lesion or an enlarged lesion on follow-up mammogram should undergo prompt biopsy [4]. Varas et al. [10] reported that when probably benign lesions showed an increase in size, loss of distinct borders, increase in the number of microcalcifications, new forms of calcifications, newly appeared mass within microcalcifications and palpable lumps, prompt biopsy was recommended even if it had been previously assessed as probably benign. Recently several reports demonstrated that probably benign lesions with interval growth should undergo biopsy or excision [23–26]. Moon et al. [23] recommended prompt biopsy if probably benign lesions showed changes in lesion characteristics as well as interval growth on follow-up ultrasonography because the malignancy rate increased to 38.5%. In our study, a total of 13 masses showed interval growth on follow-up ultrasonography and one was malignant (7.7%, 1/13). Therefore, further study such as surgery, US-VAE or US-CNB is recommended when probably benign lesions show interval growth even if initial biopsy results are benign.

In this study, surgically confirmed phyllodes tumor were regarded as borderline lesions because the management and behavior of benign phyllodes are different with fibroadenoma. Phyllodes tumor should be treated by wide surgical excision with clear margin whereas fibroadenoma is effectively managed by simple enucleation [27]. Also it has a tendency to recur, metastasize regardless of its histology and malignant potential in some of cases [28,29]. Therefore, we considered and analyzed benign phyllodes tumor as borderline lesion.

There were several limitations in this study. First, this study was a retrospective study with a relatively small number of patients. Second, ultrasonography is an operator-dependent process and there may be measurement variability among radiologists who perform ultrasonography.

In conclusion, US-CNB of probably benign breast lesions with benign biopsy results 2 cm or larger was accurate (98.6%) enough to rule out malignancy. But, it was difficult to rule out borderline lesions even after they were diagnosed as benign through US-CNB.

ORCID: Hyun Kyung Jung: http://orcid.org/0000-0001-6086-7771; Hee Jung Moon: http://orcid.org/0000-0002-5643-5885; Min Jung Kim: http://orcid.org/0000-0003-4949-1237; Eun-Kyung Kim: http://orcid.org/0000-0002-3368-5013

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

References
1. Benson SR, Blue J, Judd K, Harman JE. Ultrasound is now better than mammography for the detection of invasive breast cancer. Am J Surg 2004;188:381-385.
2. Costantini M, Belli P, Lombardi R, Franceschini G, Mule A, Bonomo
L. Characterization of solid breast masses: use of the sonographic breast imaging reporting and data system lexicon. J Ultrasound Med 2006;25:649-659.

3. Leconte I, Feger C, Galant C, Berliere M, Berg BV, D’Hoore W, et al. Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. AJR Am J Roentgenol 2003;180:1675-1679.

4. American College of Radiology. Breast imaging reporting and data system (BI-RADS) Atlas. 4th ed. Reston, VA: American College of Radiology, 2003.

5. Wai CJ, Al-Mubarak G, Homer MJ, Goldkamp A, Samenfeld-Specht M, Lee Y, et al. A modified triple test for palpable breast masses: the value of ultrasound and core needle biopsy. Ann Surg Oncol 2013;20:850-855.

6. Prutki M, Stern-Padovan R, Jakic-Razumovic J, Potocki K, Badovinac-Crnjevic T, Golubic AT. Ultrasound guided breast biopsy: a retrospective study and literature review. Lijec Vjesn 2012;134:270-275.

7. Schueller G, Jaromi S, Ponhold L, Fuchsjaeger M, Memarsadeghi M, Rudas M, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology 2008;248:406-413.

8. Bolivar AV, Alonso-Bartolome P, Garcia EO, Ayensa FG. Ultrasound-guided core needle biopsy of non-palpable breast lesions: a retrospective analysis in 204 cases. Acta Radiol 2005;46:690-695.

9. Parker SH, Jobe WE, Dennis MA, Stavros AT, Johnson KK, Yakes WF, et al. US-guided automated large-core breast biopsy. Radiology 1993;187:507-511.

10. Varas X, Leborgne F, Leborgne JH. Nonpalpable, probably benign lesions: role of follow-up mammography. Radiology 1992;184:409-414.

11. Sickles EA. Periodic mammographic follow-up of probably benign lesions: results in 3, 184 consecutive cases. Radiology 1991;179:463-468.

12. Sickles EA. Nonpalpable, circumscribed, noncalcified solid breast masses: likelihood of malignancy based on lesion size and age of patient. Radiology 1994;192:439-442.

13. Kim MJ, Park BW, Kim SJ, Youk JH, Kwak JY, Moon HJ, et al. Long-term follow-up results for ultrasound-guided vacuum-assisted removal of benign palpable breast mass. Am J Surg 2010;199:1-7.

14. Kim EK, Ko KH, Oh KK, Kwak JY, You JK, Kim MJ, et al. Clinical application of the BI-RADS final assessment to breast sonography in conjunction with mammography. AJR Am J Roentgenol 2008;190:1209-1215.

15. Leung JW, Sickles EA. The probably benign assessment. Radiol Clin North Am 2007;45:773-789.

16. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995;196:123-134.

17. Graf O, Helbich TH, Hopf G, Graf C, Sickles EA. Probably benign breast masses at US: is follow-up an acceptable alternative to biopsy? Radiology 2007;244:87-93.

18. Mainiero MB, Goldkamp A, Lazarus E, Livingston L, Koelliker SL, Schepps B, et al. Characterization of breast masses with sonography: can biopsy of some solid masses be deferred? J Ultrasound Med 2005;24:161-167.

19. Park YM, Kim EK, Lee JH, Ryu JH, Han SS, Choi SJ, et al. Palpable breast masses with probably benign morphology at sonography: can biopsy be deferred? Acta Radiol 2008;49:1104-1111.

20. Sickles EA. Management of probably benign breast lesions. Radiol Clin North Am 1995;33:1123-1130.

21. Hall FM. Follow-up of probably benign breast lesions. Radiology 2000;217:303-305.

22. Leung JW, Sickles EA. Multiple bilateral masses detected on screening mammography: assessment of need for recall imaging. AJR Am J Roentgenol 2000;175:23-29.

23. Moon HJ, Kim EK, Kwak JY, Yoon JH, Kim MJ. Interval growth of probably benign breast lesions on follow-up ultrasound: how can these be managed? Eur Radiol 2011;21:908-918.

24. Gordon PB, Gagnon FA, Lanzkowsky L. Solid breast masses diagnosed as fibroadenoma at fine-needle aspiration biopsy: acceptable rates of growth at long-term follow-up. Radiology 2003;229:233-238.

25. Jackson VP. Management of solid breast nodules: what is the role of sonography? Radiology 1995;196:14-15.

26. Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim MJ. Interval growth of probably benign breast lesions on follow-up ultrasound: how can these be managed? Eur Radiol 2011;21:908-918.

27. Steinback JK, Gagnon FA, Lanzkowsky L. Solid breast masses diagnosed as fibroadenoma at fine-needle aspiration biopsy: acceptable rates of growth at long-term follow-up. Radiology 2003;229:233-238.

28. Jackson VP. Management of solid breast nodules: what is the role of sonography? Radiology 1995;196:14-15.

29. Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim SJ, Sohn YM, et al. Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical, and pathological characteristics. Ultrasound Med Biol 2010;36:551-559.

30. Jackson VP. Management of solid breast nodules: what is the role of sonography? Radiology 1995;196:14-15.